257 related articles for article (PubMed ID: 17938138)
21. [Etanercept in rheumatoid arthritis patients with a poor therapeutic response to infliximab].
Sanmartí R; Gómez-Puerta JA; Rodríguez-Cros JR; Albaladejo C; Muñoz-Gómez J; Cañete JD
Med Clin (Barc); 2004 Mar; 122(9):321-4. PubMed ID: 15033049
[TBL] [Abstract][Full Text] [Related]
22. Treatment persistence with adalimumab, etanercept, or infliximab in combination with methotrexate and the effects on health care costs in patients with rheumatoid arthritis.
Tang B; Rahman M; Waters HC; Callegari P
Clin Ther; 2008 Jul; 30(7):1375-84. PubMed ID: 18691998
[TBL] [Abstract][Full Text] [Related]
23. Drug-specific and time-dependent risks of bacterial infection among patients with rheumatoid arthritis who were exposed to tumor necrosis factor alpha antagonists.
Curtis JR; Xi J; Patkar N; Xie A; Saag KG; Martin C
Arthritis Rheum; 2007 Dec; 56(12):4226-7. PubMed ID: 18050253
[No Abstract] [Full Text] [Related]
24. Mycobacterial infections in patients treated with tumor necrosis factor antagonists in South Korea.
Lee SK; Kim SY; Kim EY; Jung JY; Park MS; Kim YS; Kim SK; Chang J; Kang YA
Lung; 2013 Oct; 191(5):565-71. PubMed ID: 23728990
[TBL] [Abstract][Full Text] [Related]
25. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register.
Dixon WG; Watson K; Lunt M; Hyrich KL; Silman AJ; Symmons DP;
Arthritis Rheum; 2006 Aug; 54(8):2368-76. PubMed ID: 16868999
[TBL] [Abstract][Full Text] [Related]
26. Adalimumab, etanercept, and infliximab utilization patterns and drug costs among rheumatoid arthritis patients.
Carter CT; Changolkar AK; Scott McKenzie R
J Med Econ; 2012; 15(2):332-9. PubMed ID: 22168788
[TBL] [Abstract][Full Text] [Related]
27. Anti-nuclear antibodies, anti-DNA and C4 complement evolution in rheumatoid arthritis and ankylosing spondylitis treated with TNF-alpha blockers.
Gonnet-Gracia C; Barnetche T; Richez C; Blanco P; Dehais J; Schaeverbeke T
Clin Exp Rheumatol; 2008; 26(3):401-7. PubMed ID: 18578960
[TBL] [Abstract][Full Text] [Related]
28. Heart failure in rheumatoid arthritis: rates, predictors, and the effect of anti-tumor necrosis factor therapy.
Wolfe F; Michaud K
Am J Med; 2004 Mar; 116(5):305-11. PubMed ID: 14984815
[TBL] [Abstract][Full Text] [Related]
29. Focus on adverse events of tumour necrosis factor alpha blockade in juvenile idiopathic arthritis in an open monocentric long-term prospective study of 163 patients.
Gerloni V; Pontikaki I; Gattinara M; Fantini F
Ann Rheum Dis; 2008 Aug; 67(8):1145-52. PubMed ID: 17981916
[TBL] [Abstract][Full Text] [Related]
30. Anti-TNF agents for rheumatoid arthritis.
Seymour HE; Worsley A; Smith JM; Thomas SH
Br J Clin Pharmacol; 2001 Mar; 51(3):201-8. PubMed ID: 11298065
[TBL] [Abstract][Full Text] [Related]
31. TNF blockade in the treatment of rheumatoid arthritis: infliximab versus etanercept.
Mikuls TR; Moreland LW
Expert Opin Pharmacother; 2001 Jan; 2(1):75-84. PubMed ID: 11336570
[TBL] [Abstract][Full Text] [Related]
32. Potential role of pharmacogenetics in anti-TNF treatment of rheumatoid arthritis and Crohn's disease.
Kooloos WM; de Jong DJ; Huizinga TW; Guchelaar HJ
Drug Discov Today; 2007 Feb; 12(3-4):125-31. PubMed ID: 17275732
[TBL] [Abstract][Full Text] [Related]
33. Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor alpha therapies: does the risk change with the time since start of treatment?
Askling J; van Vollenhoven RF; Granath F; Raaschou P; Fored CM; Baecklund E; Dackhammar C; Feltelius N; Cöster L; Geborek P; Jacobsson LT; Lindblad S; Rantapää-Dahlqvist S; Saxne T; Klareskog L
Arthritis Rheum; 2009 Nov; 60(11):3180-9. PubMed ID: 19877027
[TBL] [Abstract][Full Text] [Related]
34. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: clinical features and possible immunopathogenesis.
Collamer AN; Battafarano DF
Semin Arthritis Rheum; 2010 Dec; 40(3):233-40. PubMed ID: 20580412
[TBL] [Abstract][Full Text] [Related]
35. The efficiency of switching from infliximab to etanercept and vice-versa in patients with rheumatoid arthritis.
Cohen G; Courvoisier N; Cohen JD; Zaltni S; Sany J; Combe B
Clin Exp Rheumatol; 2005; 23(6):795-800. PubMed ID: 16396697
[TBL] [Abstract][Full Text] [Related]
36. TNF inhibitors induce discoid fibrosis in the sublining layers of the synovium with degeneration of synoviocytes in rheumatoid arthritis.
Hirohata S; Tomita T; Yoshikawa H; Kyogoku M
Rheumatol Int; 2013 Oct; 33(10):2473-81. PubMed ID: 23575549
[TBL] [Abstract][Full Text] [Related]
37. Lack of adverse effect of anti-tumor necrosis factor-α biologics in treatment of rheumatoid arthritis: 5 years follow-up.
Dewedar AM; Shalaby MA; Al-Homaid S; Mahfouz AM; Shams OA; Fathy A
Int J Rheum Dis; 2012 Jun; 15(3):330-5. PubMed ID: 22709496
[TBL] [Abstract][Full Text] [Related]
38. Effect of tumour necrosis factor alpha antagonists on serum transaminases and viraemia in patients with rheumatoid arthritis and chronic hepatitis C infection.
Peterson JR; Hsu FC; Simkin PA; Wener MH
Ann Rheum Dis; 2003 Nov; 62(11):1078-82. PubMed ID: 14583571
[TBL] [Abstract][Full Text] [Related]
39. Effects of polymorphisms in TRAILR1 and TNFR1A on the response to anti-TNF therapies in patients with rheumatoid and psoriatic arthritis.
Morales-Lara MJ; Cañete JD; Torres-Moreno D; Hernández MV; Pedrero F; Celis R; García-Simón MS; Conesa-Zamora P
Joint Bone Spine; 2012 Dec; 79(6):591-6. PubMed ID: 22480748
[TBL] [Abstract][Full Text] [Related]
40. Etanercept maintains the clinical benefit achieved by infliximab in patients with rheumatoid arthritis who discontinued infliximab because of side effects.
Iannone F; Trotta F; Montecucco C; Giacomelli R; Galeazzi M; Matucci-Cerinic M; Ferri C; Cutolo M; Maria Bambara L; Triolo G; Ferraccioli G; Valentini G; Lapadula G;
Ann Rheum Dis; 2007 Feb; 66(2):249-52. PubMed ID: 16837489
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]